Global Endometriosis Treatment Industry Set to Surge with a 3% CAGR Through 2030 | Reveals FMI Insight

The Global Endometriosis Treatment Industry, valued at an impressive US$ 2.8 billion in 2018, is on the brink of transformative expansion, with a projected Compound Annual Growth Rate (CAGR) of approximately 3% over the period 2019-2030. This forecast, unveiled by industry experts at Future Market Insights Inc., reflects the collective momentum driven by heightened awareness among women and substantial investments by key stakeholders.

The steadfast growth of this industry is propelled by the escalating prevalence of endometriosis, a condition affecting millions of women worldwide. As the demand for advanced treatment options continues to surge, industry leaders are taking the helm, focusing on pioneering therapeutic advancements and strategic product launches.

Request a Sample Copy of This Report Now.
https://www.futuremarketinsights.com/reports/sample/rep-gb-3870

Key Takeaways of Global Endometriosis Treatment Industry Study

• Based on drug, oral contraceptives contributed maximum value share to the global endometriosis treatment Industry in 2018, owing to high preference for them as a first-line therapy for patients without contraindications, and efficacy in preventing recurrence of pelvic pain and endometriosis lesions.
• High treatment efficacy and acceptance with low risk are expected to result in a notable share of hormonal therapy in the treatment type.
• The hospital pharmacies and retail pharmacies segments, collectively, hold above 60% of value share to the endometriosis treatment industry, owing to the high patient pool in hospitals and visiting retail pharmacies.
• Europe captured a notable revenue share of 37% in 2018, and is expected to be the most lucrative region in the global endometriosis treatment market during the forecast period.
• Increasing government expenditure for high growth of the medical industry in emerging economies in the Asian region is expected to drive the growth of the endometriosis treatment industry across this region.

Multiple New Indications – Imperative Strategy for Global Endometriosis Treatment Industry Players

Increasing the introduction of endometriosis drugs with multiple new indications is a major factor responsible for intense competition among market players. Several companies are focusing on launching new endometriosis treatment options to increase their product sales and expand their market share. For example, in July 2018, AbbVie Inc. introduced a new innovative product – Orilissa(elagolix) tablets, a gonadotropin-releasing hormone (GnRH) receptor antagonist for the management of moderate to severe pain associated with endometriosis, in the U.S. market.

Methodology Details Just a Click Away!
https://www.futuremarketinsights.com/request-report-methodology/rep-gb-3870

What else is in the report?

Future Market Insights (FMI) offers a unique perspective and actionable insights on the endometriosis treatment market in its latest study, presenting historical demand assessment of 2014-2018 and projections for the period of 2019-2030, based on drug (oral contraceptives, progestins, NSAIDs, GnRH analogues, LNR-IUDs, and others), treatment type (hormonal therapy and pain management), and distribution channel (hospital pharmacies, retail pharmacies, drugstores, and e-Commerce), across seven key regions of the world.

Global Endometriosis Treatment Industry Segmentation

The global endometriosis treatment industry is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.

Drug:

• Oral Contraceptives
• Progestins
• NSAIDs
• GnRH Analogues
• LNR-IUDs
• Others

Treatment Type:

• Hormonal Therapy
• Pain Management

Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Drugstores
• e-Commerce

Access Exclusive Market Insights – Purchase Now!
https://www.futuremarketinsights.com/checkout/3870

Author

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges clients face and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI is the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5,000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:      

Nandini Singh Sawlani

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube